TW202114684A - 增強癌症病患之抗腫瘤免疫之方法 - Google Patents

增強癌症病患之抗腫瘤免疫之方法 Download PDF

Info

Publication number
TW202114684A
TW202114684A TW109120659A TW109120659A TW202114684A TW 202114684 A TW202114684 A TW 202114684A TW 109120659 A TW109120659 A TW 109120659A TW 109120659 A TW109120659 A TW 109120659A TW 202114684 A TW202114684 A TW 202114684A
Authority
TW
Taiwan
Prior art keywords
cancer
chemotherapy
immune
group
tumor
Prior art date
Application number
TW109120659A
Other languages
English (en)
Chinese (zh)
Inventor
派屈克 喬瑟夫 羅柏茲
安 賴
潔西卡 Ａ 索倫堤諾
Original Assignee
美商G1治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商G1治療公司 filed Critical 美商G1治療公司
Publication of TW202114684A publication Critical patent/TW202114684A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hospice & Palliative Care (AREA)
TW109120659A 2019-06-18 2020-06-18 增強癌症病患之抗腫瘤免疫之方法 TW202114684A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863153P 2019-06-18 2019-06-18
US62/863,153 2019-06-18
US201962907375P 2019-09-27 2019-09-27
US62/907,375 2019-09-27

Publications (1)

Publication Number Publication Date
TW202114684A true TW202114684A (zh) 2021-04-16

Family

ID=74040931

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109120659A TW202114684A (zh) 2019-06-18 2020-06-18 增強癌症病患之抗腫瘤免疫之方法

Country Status (9)

Country Link
US (1) US20220175787A1 (https=)
EP (1) EP3986410A4 (https=)
JP (1) JP7812232B2 (https=)
KR (1) KR20220024540A (https=)
CN (1) CN114222577A (https=)
AU (1) AU2020296087A1 (https=)
CA (1) CA3143339A1 (https=)
TW (1) TW202114684A (https=)
WO (1) WO2020257536A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968290T3 (da) * 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022258002A1 (zh) * 2021-06-10 2022-12-15 上海岸阔医药科技有限公司 治疗化疗相关的胃肠道副作用的化合物和方法
CN118215481A (zh) * 2021-07-01 2024-06-18 海南先声再明医药股份有限公司 晚期和/或转移性Trop-2过表达癌症患者的联合治疗
WO2023064913A1 (en) * 2021-10-14 2023-04-20 Wisconsin Alumni Research Foundation K17 as a biomarker for tumor response to immunotherapy
CN115019880B (zh) * 2022-05-05 2024-01-09 中山大学附属第一医院 一种肝癌预后模型及其构建方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102051881B1 (ko) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
DK2968290T3 (da) * 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
AU2017359333B2 (en) * 2016-11-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
IL303038B2 (en) * 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
WO2018156812A1 (en) * 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Treatment of egfr-driven cancer with fewer side effects
WO2019108589A1 (en) * 2017-11-30 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
US10122265B1 (en) 2018-01-03 2018-11-06 Intel Corporation Reducing electromagnetic interference in switching regulators
TW202327610A (zh) * 2021-08-30 2023-07-16 美商G1治療公司 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療

Also Published As

Publication number Publication date
JP7812232B2 (ja) 2026-02-09
CN114222577A (zh) 2022-03-22
EP3986410A1 (en) 2022-04-27
US20220175787A1 (en) 2022-06-09
KR20220024540A (ko) 2022-03-03
AU2020296087A1 (en) 2022-01-27
CA3143339A1 (en) 2020-12-24
JP2022536854A (ja) 2022-08-19
WO2020257536A1 (en) 2020-12-24
EP3986410A4 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
TW202114684A (zh) 增強癌症病患之抗腫瘤免疫之方法
Chu et al. Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials
Liu et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Humeau et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress
EP4101447A1 (en) Nant cancer vaccine
Chen et al. Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
Wang et al. Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
KR20240029045A (ko) 진행성 및/또는 전이성 Trop-2 과다발현 암을 갖는 환자에서의 조합 치료
WO2023114984A1 (en) Tead inhibitors and uses thereof
CN117729917A (zh) 使用akr1c3活化化合物与免疫检查点抑制剂的组合疗法
US20180021295A1 (en) Methods and materials for assessing chemotherapy responsiveness and treating cancer
WO2023034336A2 (en) Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
TW202231283A (zh) 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療
Rolle et al. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer
JP2022515128A (ja) がんの処置のための併用療法
EP4082577A1 (en) Cancer treatment method and medicine
Vergato et al. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer
EP4611821A1 (en) Methods for the detection and treatment of non-small-cell lung cancer
EP4014988A1 (en) Novel treatment and prevention of disease based on immunological memory
HK40066320A (zh) 增强癌症患者中抗肿瘤免疫的患者选择
JP2022522994A (ja) がんの処置のための組合せ物
Vergato et al. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancer
Leonardi Study of molecular pathways modulating autophagy in lung tumor cells and their impact on NSCLC tumor progression
Campos-Parra et al. Repurposed Drugs Targeting Cancer Signaling Pathways: Dissecting New Mechanisms of Action Through in Vitro and in Vivo Analyses. Lausanne: Frontiers Media SA. doi: 10.3389
HK40066138A (zh) 对携带egfr或her2外显子20插入的癌细胞具有抗肿瘤活性的化合物